Pipeline
| TARGET | INDICATION | PROGRAM | PRECLINICAL | PHASE I | PHASE II | PHASE III | APPROVAL |
|---|---|---|---|---|---|---|---|
| Cerebellar Ataxia | Symptomatic | SLX-100 |  | 2027 | |||
| Chronic | SLX-200 |  | 2028 | ||||
| Nerve Injuries | Trauma | SOL-100 |  | TBD | |||
| CIPN | SOL-200 |  | TBD |
For SLX-100 and SLX-200, we will be referencing safety and dosing from previously published studies not conducted by Solaxa in our 505b2 expedited regulatory submission
Issued patent protection
- through 2036: 4-Aminopyridine
- through 2038: Confidential